Phillis Wu
Hematology & Oncology · Sylmar, CANPI 1174716328
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,996 of the $2,341 with a category attached, or 85.3%. It is spread thinly across 32 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 91 payments — averaging $25.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$317
- Johnson & Johnson$266
- AstraZeneca$241
- Seagen Inc.$211
- Lilly USA, LLC$131
- Regeneron Healthcare Solutions, Inc.$96
- plus $1K from 26 others
What the payments were for
- Food & beverage$1,99685%
- Education$34515%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 12 | $317 |
| Johnson & Johnson(2 entities) | 7 | $266 |
| AstraZeneca(2 entities) | 11 | $241 |
| Seagen Inc. | 7 | $211 |
| Lilly USA, LLC | 2 | $131 |
| Regeneron Healthcare Solutions, Inc. | 3 | $96 |
| Incyte Corporation | 4 | $83 |
| Merck | 3 | $83 |
| E.r. Squibb & Sons, L.L.C. | 5 | $82 |
| Eisai Inc. | 4 | $81 |
| ADC Therapeutics America, Inc. | 3 | $80 |
| Genentech USA, Inc. | 3 | $60 |
| AbbVie | 2 | $55 |
| Sanofi | 2 | $46 |
| Pfizer | 3 | $44 |
| Foundation Medicine, Inc. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $42 |
| Bayer | 2 | $35 |
| Geron Corporation | 1 | $31 |
| Gilead | 1 | $31 |
| Genmab U.S., Inc. | 1 | $30 |
| Dendreon Pharmaceuticals LLC | 1 | $30 |
| Amgen | 1 | $29 |
| Tersera Therapeutics LLC | 1 | $29 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Novartis | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Puma Biotechnology, Inc. | 1 | $20 |
| Array Biopharma Inc | 1 | $18 |
| Agios Pharmaceuticals, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
How this compares
$2,341 in reported general payments places this provider in the 40th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Sylmar
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.